GNIPST Bulletin 47.3

24-07-2015

GGGNNNIIIPPPSSSTTT BBBUUULLLLLLEEETTTIIINNN 22200011155524th July, 2015 Volume No.: 47 Issue No.: 03

Vision

TO REACH THE PINNACLE OF GLORY AS A CENTRE OF EXCELLENCE IN THE FIELD OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES BY KNOWLEDGE

BASED LEARNING AND PRACTICE

Contents Message from PRINCIPAL Editorial board Historical article News Update Knowledge based Article Disease Related Breaking

News Upcoming Events Drugs Update Campus News Students Section Editors Note Archive

GNIPST Photo Gallery For your comments/contribution OR For Back-Issues, mailto:[email protected]

GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

W e bs i t e : ht t p: / / gni ps t. a c. i n

24-07-2015

MESSAGE FROM PRINCIPAL

"It can happen. It does happen. But it can't happen if you quit." Lauren Dane.

We are what we repeatedly do. Excellence then is not an act, but a habit. Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the last years editors and congratulate the newly selected editors for the current year.

Our first consideration is always in the best interest of the students. Our goal is to promote academic excellence and continuous improvement.

I believe that excellence in education is aided by creating a learning environment in which all learners are supported in maximizing their potential and talents. Education needs to focus on personalized learning and instruction, while promoting an education system that is impartial, universally accessible, and meeting the needs of all students.

It is of paramount importance that our learners have sufficient motivation and encouragement in order to achieve their aims. We are all very proud of you, our students, and your accomplishments and look forward to watching as you put your mark on the profession in the years ahead.

The call of the time is to progress, not merely to move ahead. Our progressive Management is looking forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in this direction and fruits of these efforts will be received by our students in the near future. Our Teachers are committed and dedicated for the development of the institution by imparting their knowledge and play the role of facilitator as well as role model to our students.

The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic needs of our students.

I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the opportunities and meet the challenges with purpose and determination.

Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on this path.

My best wishes to all.

Dr. A. Sengupta

Click here to go at the top

1

24-07-2015

EDITORIAL BOARD

CHIEF EDITOR DR. ABHIJIT SENGUPTA EDITOR MS. JEENATARA BEGUM ASSOCIATE EDITOR MR. DIPANJAN MANDAL

HISTORICAL ARTICLE Sergei Winogradsky (1856 1953)

Sergei Winogradsky founded microbial ecology and he was a founding father of microbiology. In an unusually long scientific career, he:

Discovered chemosynthesis an entirely new mode of life, in whichthe energy to build organic molecules comes from chemicalreactions rather than from sunlight in the morefamiliar photosynthesis.

Invented the Winogradsky column. Discovered and isolated nitrogen fixing bacteria in soil that make

nitrates available to green plants. Founded microbial ecology, where the interactions of microbes in

cycles with their natural environments are studied holistically.BeginningsSergei Nikolaievich Winogradsky was born on September 1, 1856in Kiev, which was then in the Russian Empire and is nowUkraines capital city.His family were wealthy landowners and his father, NikolaiKonstantinovitch Winogradsky, was the head of a bank. Hismothers name was Natalia Viktorovna Skoropadskaia.Winogradsky received the education a wealthy boy could expectin those days, so the classics Greek and Latin were consideredmuch more important that the sciences.Winogradsky was deeply unhappy at school, because he did notenjoy the classics indeed he hated every minute of being forced tolearn the ancient languages. Despite his dislike of the curriculum,


2

24-07-2015

he graduated from high school at the top of his class with a gold medal. At the age of 17 he began a law degree at the University of Kiev. It did not take long for him to decide that law was just as boring as the classics, so he switched to science. Unfortunately, the science lectures at Kiev were monotonous, and, aged 19, he added science to the growing list of subjects he had dumped! He now decided that he owed it to the world to become a musical maestro! He gave up life in Kiev and moved to the capital of the Russian Empire, Saint Petersburg, to study piano at the Imperial Conservatoire of Music. At the age of 21, as youve probably guessed by now, he decided that music was a bit of a bore (he actually had significant musical talent, but he was not a maestro) and maybe science would be the most interesting field for his mercurial mind. He enrolled at the University of Saint Petersburg, and there, for the first time, he encountered talented scientists. And now there was no going back. He discovered that science was his true vocation, particularly botany and microbiology he found the microbiological work of Louis Pasteur in France especially interesting and inspiring. In 1881, aged 24, he graduated with a degree in science, then began post-graduate work investigating the effects of nutrients on yeast growth. In 1884 he obtained a masters degree in botany. Winogradskys reputation as a promising scientist reached the ears of Heinrich Anton de Bary, a microbiologist and the founder of modern mycology (the study of fungi). De Bary engaged Winogradsky in 1885 as a research worker at the University of Strasbourg, which was then located in Germany, but is now in France. By 1887, the 31 year old Winogradsky had discovered that Beggiatoa did not obtain energy by any previously known method. Beggiatoas energy came from a chemical reaction between hydrogen sulfide, present in sulfurous waters, and oxygen. The reaction also produced sulfur and water.


3

24-07-2015

Winogradsky also observed that the bacteria only functioned when carbon dioxide was present this was to prove important. The Winogradsky Column During his time in Strasbourg, Winogradsky invented the Winogradsky Column, which is still used today to learn which communities of bacteria are present in a sample. It consists of a glass cylinder half-filled with mud from a river or lake, topped up with water. A number of ingredients, such as sodium sulfate, calcium carbonate, and cellulose (newspaper) are added to provide sources of nutrition for bacteria. Nitrogen Fixing Bacteria and the Discovery of Chemosynthesis In 1888, Winogradsky moved from Strasbourg to the Swiss Polytechnic Institute in Zurich, Switzerland; there he began studying bacteria involved in nitrogen fixing. During three years in Zurich, Winogradsky discovered three entirely new genera of nitrogen fixing bacteria. He also provided chemical proof of two separate steps in nitrogen fixing: firstly, the oxidation of ammonium to form nitrite, then the oxidation of nitrite to form nitrate. And he made his greatest discovery: chemosynthesis. Chemosynthesis Most of us are familiar with photosynthesis the process in which organisms use light as the energy source to build organic matter the molecules of carbon-based life from carbon dioxide and water. Winogradsky discovered an entirely new process chemosynthesis in which organisms use chemical reactions rather than light as the energy source to build organic matter. In the case of Beggiatoa, the energy is produced by the reaction of hydrogen sulfide with oxygen. In the case of nitrogen fixing bacteria, the energy is produced by the oxidation of nitrogen and its compounds. Sergei Winogradsky died in his sleep at the age of 96 in Brie-Comte-Robert, France, on February 25, 1953.


4

24-07-2015

NEWS UPDATE Clues to human molecular interactions: 24th July,

2015 Scientists have unraveled how an important plant protein, known as TOPLESS, interacts with other molecules responsible for turning genes off. The findings in plants provide a general model across species for this type of gene silencing, which is linked to several vital biological functions in humans.

Know it's a placebo? Study shows the 'medicine' could still work: 24th July, 2015 A new study shoes that under certain conditions, research participants who know a treatment they are receiving to ease pain is a placebo with no medical value, it still works.

Brain structure reveals ability to regulate emotions: 24th July, 2015 People diagnosed with a personality disorder may find it difficult to function in society due to difficulties in regulating emotions -- but also healthy individuals differ in how often they become irritated, angry or sad. Scientists have published a study where they show that the affected brain areas in people with a clinical diagnosis are also affected in healthy individuals.

Toxin from salmonid fish has potential to treat cancer: 24th July, 2015 Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer.

Patient satisfaction is good indicator of success after spinal surgery: 24th July, 2015 Patient satisfaction ratings after surgery for spinal degenerative disease--especially in terms of reduced pain and disability--are a


5

24-07-2015

good indicator of the procedure's effectiveness, reports a new study.

Prostate cancer: Scientists discover why some tumous are resistant to radiotherapy: 24th July, 2015 Scientists believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy. It is hoped that this new development could pave the way for more effective treatments -- allowing a lower dose of radiotherapy to be used while prolonging the lives of thousands of men.

Research analyzes impact of case volume on outcomes for DVT treatment: 24th July, 2015 Patients who have lower extremity proximal deep vein thrombosis, or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based clot removal -- also referred to as catheter-directed thrombolysis -- rather than solely being treated with traditional blood-thinning medications. A study has found that a higher volume of CDT cases annually was associated with lower in-hospital mortality rates and lower intracranial hemorrhage.

Diagnosis of psychiatric disorders not as important as outcomes: 24th July, 2015 Nailing the diagnosis of a psychiatric disorder may not be important in prescribing effective treatment, according a clinical researcher. The National Institute of Mental Health estimates that nearly one in five Americans suffers from mental illnesses as defined in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders.


6

24-07-2015

Scientists discover first 'DNA ambulance': 24th July, 2015 Researchers have discovered how severely damaged DNA is transported within a cell and how it is repaired. It's a discovery that could unlock secrets into how cancer operates.

Breakthrough experimental therapy to treat colon cancer, chronic inflammatory bowel disease: 23rd July, 2015 A groundbreaking experimental therapy has been discovered that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information. For detail mail to editor

KNOWLEDGE BASED ARTICLE

First anti-inflammatory 3000 B.C. 1500 B.C.

c3000 1500 BC: Willow is used as a medicine by ancient civilisations like the Sumerians and Egyptians. The Ebers papyrus, an ancient Egyptian medical text, refers to willow as an anti-inflammatory or pain reliever for non-specific aches and pains. c400 BC: In Greece, Hippocrates administers willow leaf tea, which contains the natural compound from which aspirin is derived, to women to ease the pain of childbirth. 1763: The Royal Society publishes a report detailing five years of experiments on the use of dried, powdered willow bark in curing fevers, submitted by Edward Stone, a vicar in Chipping Norton, Oxfordshire.


7

24-07-2015

1828: Joseph Buchner, professor of pharmacy at Munich University, Germany, succeeds in extracting the active ingredient from willow, producing bitter tasting yellow crystals that he names salicin. 1830: Salicin is also found in the meadowsweet flower by Swiss pharmacist Johann Pagenstecher and later by German researcher Karl Jacob Lwig. 1853: French chemist Charles Frdric Gerhardt determines the chemical structure of salicyclic acid and chemically synthesises acetylsalicylic acid. 1876: The first rigorous clinical trial of salicin finds that it induces remission of fever and joint inflammation in patients with rheumatism (Lancet 1876;1:383). 1897: While working for pharmaceutical company Bayer, German chemist Felix Hoffmann, possibly under the direction of colleague Arthur Eichengrn, finds that adding an acetyl group to salicylic acid reduces its irritant properties and Bayer patents the process. 1899: Acetylsalicyclic acid is named Aspirin by Bayer. The letter A stands for acetyl, spir is derived from the plant known as Spiraea ulmaria (meadowsweet), which yields salicin, and in was a common suffix used for drugs at the time of the first stable synthesis of acetylsalicylic acid. 1950: Aspirin enters the Guinness World Records for being the most frequently sold painkiller. 1971: John Vane, professor of pharmacology at the University of London, publishes research describing aspirins mechanism of action (dose-dependent inhibition of prostaglandin synthesis) (Nature New Biology 1971;231:232). He later wins a Nobel prize (1982) for this work, along with Bengt Samuelsson and Sune Bergstrm. 1974: Data from the first randomised controlled trial of aspirin in the secondary prevention of death from heart attack show a reduction in total mortality of 12% at 6 months and 25% at 12 months but the results are statistically inconclusive (BMJ 1974;1:436).


8

24-07-2015

1991 and 1993: Results from the CPS (cancer prevention study)-II, a large US prospective cohort study, confirm the cancer benefits of aspirin seen in smaller observational studies (NEJM 1991;325:1593 and Cancer Research1993;53:1322). 1997: Results from the CAST (Chinese acute stroke trial) study of early aspirin use in 20,000 patients with acute ischaemic stroke show that aspirin started early in hospital produces a small but definite net benefit (Lancet 1997; 349:1641). 1998: Results from the HOT (hypertension optimal treatment) trial show that aspirin significantly reduces major cardiovascular events in hypertensive patients, with the greatest benefit seen in preventing heart attacks. The incidence of non-fatal major bleeds was twice as common (Lancet 1998;351;1755). 2005: Results from WHS (womens health study), a large, primary-prevention trial among women, suggest that aspirin lowers the risk of stroke without affecting the risk of heart attack or death from cardiovascular causes (NEJM2005;352:1293). The WHS was conducted by investigators from Harvard Medical School. 2009: A meta-analysis by the ATT (antithrombotic trialists) collaboration suggests that aspirin has substantial overall benefit in secondary prevention but in primary prevention, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds (Lancet 2009;373:1849). 2011: A meta-analysis of eight clinical trials finds that, after five years of follow-up, trial participants who took aspirin daily for a mean of four years have a 44% reduced risk of dying from cancer compared with participants who took a placebo (Lancet 2011;377:31). 2013: Follow-up results of the WHS confirm that long-term use of alternate day low-dose aspirin results in a 42% reduction in colorectal cancer incidence, with benefits starting to appear after 10 years. The results also show increased risk of gastrointestinal bleeding and peptic ulcers (Annals of Internal Medicine 2013;159:77).


9

24-07-2015

2014: A meta-analysis suggests that long-term prophylactic use of aspirin has a favourable benefitharm profile and leads to a dramatic reduction in the incidence of bowel, stomach and oesophageal cancer (Annals of Oncology, online 5 August 2014). 2015: Results expected from the ARRIVE (aspirin to reduce risk of initial vascular events) study. 2018: Results expected from the ASPREE (aspirin in reducing events in the elderly) study to determine whether the potential benefits of low-dose aspirin outweigh the risks in healthy people older than 70 years of age.

Jeenatara Begum Assistant Professor

GNIPST

DISEASE RELATED BREAKING NEWS Middle East Respiratory Syndrome coronavirus

(MERS-CoV) Saudi Arabia: 24th July, 2015 Between 1 and 14 July 2015, the National IHR Focal Point for the Kingdom of Saudi Arabia notified WHO of 6 additional cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Read more

UPCOMING EVENTS 61st IPSF World Congress sponsored by Indian Pharmaceutical

Association (IPA) at Marriott Hotel, Hyderabad, India is going to on 30th July to 9th August, 2015.

For further details please visit www.ipsf2015.org


10

24-07-2015

DRUGS UPDATES FDA Approves Praluent (alirocumab) to Treat

Certain Patients with High Cholesterol: 16th July, 2015 The U.S. Food and Drug Administration approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Read more

CAMPUS NEWSFAREWELL PROGRAMME:

On 15th May 2015 GNIPST clebrated the farewell programme Sesh Chithi for the final year students of M.Pharm, M.Sc, B.Pharm, B.Sc and BHM.

JIS SAMMAN 2015 On 11th May, 2015 GNIPST attended the JIS SAMMAN 2015.

JIS SAMMAN Awards: Best College (Non Engineering):

GNIPST Best Principal:

Dr (Prof.) Avijit Sengupta Best HOD:

Mr. Jaydip Ray Best Faculty:

Mr. Debabrata Ghoshdastidar (Pharmacy)Dr. Swati Chakraborty (Life Sciences)

Best faculty since inception:Mr. Jaydip Ray

Best Office Staff:Ms. Jaya Banerjee

Best technical Assistant:


11

24-07-2015

Mr. Somnath Majhi College Blue:

Avik Paul Highest DGPA of 2014:

B.Pharm:Purbali Chakraborty (4th year) Diksha Kumari (3rd year) Aishika Dutta (2nd year) Sampita Paul (1st year) M.Pharm: Aritra Mukherjee (Pharmaceutical Chemistry) Mounomukhar Bhattacharya (Pharmacology) B.Sc (Biotechnology): Papiya Saha (3rd year) Shomasree Das (2nd year) Ayanita Basak (1st year) B.Sc (Microbiology): Bonhisikha Chatterjee (3rd year) Riaz Hossain (2nd year) Soumi Chowdhury (1st year) BHM: Bishal Roy (3rd year) Shreyabhanja Chowdhury (2nd year) Recitation:

Udita Majumder Debate:

Srijita Roy Poushali Ganguly Quiz:

Arani Ray Dipayan Nath Band:

Syantan Ghoswami Anurag Ghosh


12

24-07-2015

Atanu Mondal Arka Khamaru Ritobroto Paul Abhirup Dasgupta

Fashion: Md. Nadeem Shah Koustav Sarkar Shaksar Saha Avirup Dasgupta Ranit Kundu Namrata Ganguly Shreyasee Mitra Chandrika Saha Debopriya Chatterjee Riya Taran

Innovative Modeling: Ankit Chowdhury Kartik Koley Mudasar Manna Dipan Chaterjee Abhishek Singh Kaustav Pal Manojit Dutta

SPIRIT JIS 2015 On 03th to 05th April, 2015 JIS organised SPIRIT JIS 2015. GPAT 2015 Result:

The following B.Pharm. final year students have qualified, GPAT-2015. We congratulate them all. Diksha Kumari Rupanjay Bhattacharya Avik Paul Xtasy 2015: GNIPST is going to organize the Tech Fest Xtasy 2015 from 30th March, 2015 to 1st April, 2015.


13

24-07-2015

FINISHING SCHOOL TRAINING PROGRAMME: The FINISHING SCHOOL TRAINING PROGRAMME is going to organize by the Entrepreneurship Development Cell and Training & Placement Cell, GNIPST in collaboration with Indian Pharmacy Graduates Association (IPGA), Bengal Branch from 21st February to 11th April, 2015 at GNIPST Auditorium. On 21

st February, 2015 the Finishing School Training Programme of

GNIPST was inaugurated by Sri Soumen Mukhopadhyay, Deputy Director, Drug Control Office, Goutam Kr. Sen, President, IPGA, Mr. Subroto Saha, Asst. Directorate, Drug Control Office, Mr. Ranendra Chakraborty, Sales Manager and Associate Director Dr. Reddys Laboratory. On 28th February, 2015 Dr. D. Roy, Former Deputy Drug Controller, Mr. Sujoy Chakraborty, divisional Therapy Manager, Cipla and Mr. Vikranjit Biswas, Senior Manager, Learning & Development, Cipla delivered their valuable lectures in the 2nd day FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 14th March, 2015 Mr. Milindra Bhattacharya, Senior Manager, QA & QC, Emami Ltd. and Mr. Joydev Bhoumik, Manager, Operation, Ranbaxy Laboratory Limited delivered their valuable lectures in the 3rd day FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 21st March, 2015 Mr. Tridib Neogi, Associate Vice-President (Quality Assurance), Albert David Ltd. delivered his valuable lectures in the 4th FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 28th March, 2015 Dr. Gautam Chaterjee, an Alumni of Jadavpur University and presently associated with NIPER delivered his valuable lectures in the 5th FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 11th April, 2015 the closing ceremony of the FINISHING SCHOOL TRAINING PROGRAMME was held in GNIPST Auditorium.


14

24-07-2015

JOBS: All the students of Final Year B. Pharm and M. Pharm are hereby informed that an interview will be conducted on 23rd May, 2015 by Standard Pharmaceuticals Ltd. GSK for post: Production, QA, QC. All the students of Final Year B. Pharm and M. Pharm are hereby informed that an interview will be conducted by GSK for sales and marketing job. Details given below:

Date: 27.03.2015Time: 09:45 amVenue : GSK Consumer Healthcare Limited, Unit No. 208,

2nd Floor, Ecospace Campus B (3 B), New Town, Rajarhat, 24 Pgs (N). Kolkata-700156.

THYROCARE provisionally selected 15 students from JIS Group. Amongst these, 3 students of B. Sc (H) Biotechnology and M. Sc Biotechnology have been selected. Ipsita Mondal (M. Sc Biotechnology)Debriti Paul (M. Sc Biotechnology)Debopriya Chatterjee {B. Sc (H) Biotechnology}

The final year students of B.Pharm (31 students) and B.Sc (11 students) attended the pooled campus drive of Abbott India Ltd. on 10th March, 2015 at Jadavpur University. Among them 17 students have gone through to the final round of this pooled campus drive and short listed for final selection.

ACHIEVEMENT: Congratulations to Anurag Chanda, student of B.Pharm final year

who have got the 1st prize in poster presentation event in Prakriti 2015 at Department of Agricultural and Food engineering, IIT, Kharagpur.

OTHERS: On 24th and 25th February, 2015 Swamiji of Gourio Mathwasdelivered some motivational lectuers in GNIPST.


15

24-07-2015

The students of GNIPST participated in the 4th Sardar JodhSinghTrophy organised by NIT on 20th February, 2015. On 8th February, 2015 Gnipst celebrated the ReunionprogrammeReminiscence Reloaded 2015.

STUDENTS SECTION WHO CAN ANSWER FIRST????

Who is the first woman to win Nobelprize unshared in medicine and

physiology?

Answer of Previous Issues Questions: Ocean Currents

Identify the person

Answer of Previous Issues Image: Omar Sharif

Send your thoughts/Quiz/Puzzles/games/write-ups or any other contributions for Students Section& answers of this Section at [email protected]


16

24-07-2015

EDITORS NOTE

It is a great pleasure for me to publish the 3rd issue of 47th Volume of GNIPST BULLETIN. All the followers of GNIPST BULLETIN are able to avail the bulletin through facebook account GNIPST bulletin I am very much thankful to all the GNIPST members and readers who are giving their valuable comments, encouragements and supports. I am also thankful to Dr. Abhijit Sengupta, Director of GNIPST for his valuable advice and encouragement. Special thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar and Mr. Soumya Bhattacharya for their kind co-operation and technical supports. Thank you Mr. Soumya Bhattacharya for the questionnaires of the student section. An important part of the improvement of the bulletin is the contribution of the readers. You are invited to send in your write ups, notes, critiques or any kind of contribution for the forthcoming special and regular issue.

ARCHIVE The general body meeting of APTI, Bengal Branch has been

conducted at GNIPST on 15th June, 2012. The program started witha nice presentation by Dr. Pulok Kr. Mukherjee, School of NaturalProducts, JU on the skill to write a good manuscript forpublication in impact journals. It was followed by nearly two hourlong discussion among more than thirty participants on differentaspects of pharmacy education. Five nonmember participantsapplied for membership on that very day.

GNIPST is now approved by AICTE and affiliated to WBUT forconducting the two years post graduate course (M.Pharm)in PHARMACOLOGY. The approved number of seat is 18.

The number of seats in B.Pharm. has been increased from 60 to120.


17

24-07-2015

AICTE has sanctioned a release of grant under ResearchPromotion Scheme (RPS) during the financial year 2012-13toGNIPST as per the details below:a. Beneficiary Institution: Guru Nanak Institution of PharmaceuticalScience & Technology.

b. Principal Investigator: Dr. LopamudraDutta.c. Grant-in-aid sanctioned:Rs. 16,25000/- only

d. Approved duration: 3 yearse. Title of the project: Screening and identification of potential

medicinal plant of Purulia & Bankura districts of West Bengal with respect to diseases such as diabetes, rheumatism, Jaundice, hypertension and developing biotechnological tools for enhancing bioactive molecules in these plants.

Activity Clubs of GNIPST: Name of Club Member Faculty SPORTS Mr. Debabrata GhoshDastidar LITERARY AND PAINTING Ms. Jeenatara Begum SCIENCE AND INNOVATIVE MODELLING

Mr. Samrat Bose

ECO Ms. Sumana Roy SOCIAL SERVICES Dr. Asis Bala PHOTOGRAPHY Ms. Sanchari Bhattacharya CULTURAL Ms. Priyanka Ray DEBATE AND EXTEMPORE Mr. Soumya Bhattacharya


18

Sergei Winogradsky (1856 1953)Beginnings

Winogradskys reputation as a promising scientist reached the ears of Heinrich Anton de Bary, a microbiologist and the founder of modern mycology (the study of fungi). De Bary engaged Winogradsky in 1885 as a research worker at the University of Stras...By 1887, the 31 year old Winogradsky had discovered that Beggiatoa did not obtain energy by any previously known method. Beggiatoas energy came from a chemical reaction between hydrogen sulfide, present in sulfurous waters, and oxygen. The reaction a...Winogradsky also observed that the bacteria only functioned when carbon dioxide was present this was to prove important.The Winogradsky Column

During his time in Strasbourg, Winogradsky invented the Winogradsky Column, which is still used today to learn which communities of bacteria are present in a sample. It consists of a glass cylinder half-filled with mud from a river or lake, topped up ...Nitrogen Fixing Bacteria and the Discovery of ChemosynthesisChemosynthesis

Clues to human molecular interactions: 24th July, 2015Scientists have unraveled how an important plant protein, known as TOPLESS, interacts with other molecules responsible for turning genes off. The findings in plants provide a general model across species for this type of gene silencing, which is linke... Know it's a placebo? Study shows the 'medicine' could still work: 24th July, 2015A new study shoes that under certain conditions, research participants who know a treatment they are receiving to ease pain is a placebo with no medical value, it still works. Brain structure reveals ability to regulate emotions: 24th July, 2015People diagnosed with a personality disorder may find it difficult to function in society due to difficulties in regulating emotions -- but also healthy individuals differ in how often they become irritated, angry or sad. Scientists have published a s... Toxin from salmonid fish has potential to treat cancer: 24th July, 2015Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer. Patient satisfaction is good indicator of success after spinal surgery: 24th July, 2015Patient satisfaction ratings after surgery for spinal degenerative disease--especially in terms of reduced pain and disability--are a good indicator of the procedure's effectiveness, reports a new study. Prostate cancer: Scientists discover why some tumous are resistant to radiotherapy: 24th July, 2015Scientists believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy. It is hoped that this new development could pave the way for more effective treatments -- allowing a lower dose of... Research analyzes impact of case volume on outcomes for DVT treatment: 24th July, 2015Patients who have lower extremity proximal deep vein thrombosis, or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based clot removal -- also referred to as catheter-directed thrombolysis -- rather than solely being... Diagnosis of psychiatric disorders not as important as outcomes: 24th July, 2015Nailing the diagnosis of a psychiatric disorder may not be important in prescribing effective treatment, according a clinical researcher. The National Institute of Mental Health estimates that nearly one in five Americans suffers from mental illnesses... Scientists discover first 'DNA ambulance': 24th July, 2015Researchers have discovered how severely damaged DNA is transported within a cell and how it is repaired. It's a discovery that could unlock secrets into how cancer operates. Breakthrough experimental therapy to treat colon cancer, chronic inflammatory bowel disease: 23rd July, 2015A groundbreaking experimental therapy has been discovered that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhib...For detail mail to editor

KNOWLEDGE BASED ARTICLEFirst anti-inflammatory

Middle East Respiratory Syndrome coronavirus (MERS-CoV) Saudi Arabia: 24th July, 2015Between 1 and 14 July 2015, the National IHR Focal Point for the Kingdom of Saudi Arabia notified WHO of 6 additional cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.Read more FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol: 16th July, 2015The U.S. Food and Drug Administration approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. CAMPUS NEWS STUDENTS SECTION

GNIPST Bulletin 47.3

Documents

Transcript of GNIPST Bulletin 47.3